Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis

NCT04123795 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT04123795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04123795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
January 21, 2020
Completion date
July 23, 2026
Enrollment
49 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

mixed guttate/plaque psoriasis, moderate chronic plaque psoriasis, severe chronic plaque psoriasis